Illumina, Inc. is engaged in providing sequencing-and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets, enabling the adoption of genomic solutions in research and clinical settings. Its DNA sequencing technology is based on its reversible terminator-based sequencing chemistry, referred to as sequencing by synthesis biochemistry. Its BeadArray technology combines microscopic beads and a substrate in a manufacturing process to produce arrays that can perform many assays simultaneously. Its sequencing applications include whole-genome sequencing kits, which sequence entire genomes of any size and complexity, and targeted resequencing kits, which can sequence exomes, specific genes, RNA or other genomic regions of interest. Its customers include genomic research centers, academic institutions, government laboratories, hospitals, pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and others.
Código de la empresaILMN
Nombre de la empresaIllumina Inc
Fecha de salida a bolsaJun 28, 2000
Fundada en2000
Director ejecutivoMr. Jacob Thaysen, Ph.D.
Número de empleados8970
Tipo de seguridadOrdinary Share
Fin del año fiscalJun 28
Dirección5200 Illumina Way
CiudadSAN DIEGO
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal92122
Teléfono18582024500
Sitio Webhttps://www.illumina.com
Código de la empresaILMN
Fecha de salida a bolsaJun 28, 2000
Fundada en2000
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.

Sin datos